三阴性乳腺癌新辅助化疗肿瘤反应的预测性临床病理与动态增强MRI表现
研究纳入73例三阴性乳腺癌患者,分析新辅助化疗前MRI特征及临床病理因素与病理完全缓解的关系。化疗前MRI均匀强化(OR 14.66)和化疗后MRI肿瘤体积缩小呈同心圆收缩模式(OR 8.63)与病理完全缓解独立相关。MRI与手术标本测量的残留肿瘤大小呈强相关(r=0.652,p<0.001),该相关在病理完全缓解组或同心圆收缩组更强。
要点
- 化疗前MRI均匀强化与三阴性乳腺癌新辅助化疗后病理完全缓解独立相关(OR 14.66)。
- 化疗后MRI肿瘤体积缩小呈同心圆收缩模式与病理完全缓解独立相关(OR 8.63)。
- MRI与手术标本残留肿瘤大小强相关,同心圆收缩组相关性更强(r=0.818,p<0.001)。
核心结论
- 化疗前MRI肿瘤均匀强化及化疗后出现同心圆收缩模式与三阴性乳腺癌患者病理完全缓解相关;MRI与手术标本残留肿瘤大小的相关性在病理完全缓解组或同心圆收缩组似乎强于非病理完全缓解组或树枝状收缩组。
研究设计与样本
- 研究纳入2009年1月至2010年12月间73例接受新辅助化疗前三阴性乳腺癌MRI、完成新辅助化疗并接受手术的患者,分析MRI特征和临床病理因素对病理反应的预测价值,并评估MRI与手术标本测量的残留肿瘤大小。
关键影像表现/征象
- 化疗前MRI显示肿瘤均匀强化。
- 化疗后MRI显示肿瘤体积缩小呈同心圆收缩模式或树枝状收缩模式。
诊断标准与关键数值
- 化疗前MRI均匀强化预测病理完全缓解的多因素分析比值比为14.66。
- 化疗后MRI同心圆收缩模式预测病理完全缓解的比值比为8.63。
- MRI与手术标本测量的残留肿瘤大小相关系数r=0.652(p<0.001)。
- 病理完全缓解组残留肿瘤大小相关系数r=0.600(p<0.001),同心圆收缩组r=0.818(p<0.001)。
- 非病理完全缓解组残留肿瘤大小相关系数r=-0.128(p=0.590),树枝状收缩组r=0.270(p=0.182)。
临床应用与阅片要点
- 化疗前MRI评估肿瘤强化方式可为预测三阴性乳腺癌新辅助化疗后病理完全缓解提供参考。
- 化疗后MRI评估肿瘤体积缩小模式(同心圆收缩或树枝状收缩)有助于预测病理完全缓解。
- MRI测量残留肿瘤大小与手术标本相关性在同心圆收缩组较强,在树枝状收缩组较弱。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study is to investigate whether clinicopathologic factors and dynamic contrast-enhanced MRI (DCE-MRI) features are associated with pathologic tumor response to neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).
MATERIALS AND METHODS: Seventy-three patients with TNBC who underwent pre-NAC MRI, completed NAC, and underwent surgery between January 2009 and December 2010 were included in the study. MRI features and clinicopathologic factors for predicting pathologic responses were analyzed, and residual tumor sizes, as measured using MRI and surgical specimens, were evaluated.
RESULTS: Of 73 study patients, 20 (27%) had a pathologic complete response (pCR). Homogeneous enhancement on pre-NAC MRI (odds ratio from multivariate analysis, 14.66) and a concentric shrinkage pattern of tumor volume reduction on post-NAC MRI (odds ratio, 8.63) were independently associated with pCR. Residual tumor sizes, as measured using MRI and surgical specimens, showed a strong correlation (r = 0.652, p < 0.001). The correlation for residual tumor sizes was stronger for patients with pCR (r = 0.600, p < 0.001) and those with a concentric shrinkage pattern (r = 0.818, p < 0.001) than for patients with a response other than near pCR or pCR (i.e., the non-pCR group) (r = -0.128, p = 0.590) and patients with a dendritic shrinkage pattern of tumor volume reduction (r = 0.270, p = 0.182).
CONCLUSION: Homogeneous enhancement of tumors on pre-NAC MRI and the presence of a concentric shrinkage pattern after NAC are associated with pCR in patients with TNBC. Residual tumor sizes on MRI and surgical specimens tended to show a stronger correlation in the pCR group or the concentric shrinkage group than in the non-pCR group or the dendritic shrinkage group.
引用
- Eom HJ, Cha JH, Choi WJ, et al. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. AJR Am J Roentgenol. 2017. PMID: 28350486. doi:10.2214/AJR.16.17125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。